

# Hypervirulent (hypermucoviscous) *Klebsiella pneumoniae* A new and dangerous breed

Alyssa S. Shon,<sup>1</sup> Rajinder P.S. Bajwa<sup>1</sup> and Thomas A. Russo<sup>1,2,3,4,\*</sup>

<sup>1</sup>Department of Medicine; University at Buffalo-State University of New York; Buffalo, NY USA; <sup>2</sup>Department of Microbiology and Immunology; University at Buffalo-State University of New York; Buffalo, NY USA; <sup>3</sup>The Witebsky Center for Microbial Pathogenesis; University at Buffalo-State University of New York; Buffalo, NY USA; <sup>4</sup>Veterans Administration Western New York Healthcare System; Buffalo, NY USA

**Keywords:** *Klebsiella pneumoniae*, hypervirulent, hypermucoviscous, pathogenesis, epidemiology, treatment, diagnosis, infection, virulence factors

**Abbreviations:** hvKP, hypervirulent *Klebsiella pneumoniae*; cKP, classic *Klebsiella pneumoniae*; CA-PLA, community-acquired pyogenic liver abscess; CP, capsular polysaccharide; CNS, central nervous system; DM, diabetes mellitus; EE, endogenous endophthalmitis; GNB, Gram-negative bacillus; IG, intra-gastric; IP, intra-peritoneal; LPS, lipopolysaccharide; NDM-1, New Delhi metallo- $\beta$ -lactamase; ST, sequence type; UTI, urinary tract infection

A new hypervirulent (hypermucoviscous) variant of *Klebsiella pneumoniae* has emerged. First described in the Asian Pacific Rim, it now increasingly recognized in Western countries. Defining clinical features are the ability to cause serious, life-threatening community-acquired infection in younger healthy hosts, including liver abscess, pneumonia, meningitis and endophthalmitis and the ability to metastatically spread, an unusual feature for enteric Gram-negative bacilli in the non-immunocompromised. Despite infecting a healthier population, significant morbidity and mortality occurs. Although epidemiologic features are still being defined, colonization, particularly intestinal colonization, appears to be a critical step leading to infection. However the route of entry remains unclear. The majority of cases described to date are in Asians, raising the issue of a genetic predisposition vs. geospecific strain acquisition. The traits that enhance its virulence when compared with "classical" *K. pneumoniae* are the ability to more efficiently acquire iron and perhaps an increase in capsule production, which confers the hypermucoviscous phenotype. An objective diagnostic test suitable for routine use in the clinical microbiology laboratory is needed. If/when these strains become increasingly resistant to antimicrobials, we will be faced with a frightening clinical scenario.


## Introduction

The majority of infections due to *Klebsiella pneumoniae* in Western countries are due to "classic" *K. pneumoniae* strains. Friedlander, in 1882, described an encapsulated bacillus isolated from the lungs of patients who died of pneumonia. This predated the Gram stain technique, which was developed in 1884.

It was initially named Friedlander's bacillus but was changed to *Klebsiella* in 1886. In the pre-antibiotic era, *K. pneumoniae* was implicated as a cause of pneumonia, especially in alcoholics and diabetic patients. It was also an established uropathogen, and a cause of biliary tract infections, osteomyelitis and bacteremia. The epidemiology of *K. pneumoniae* infections has evolved in the antibiotic era, with most infections, particularly in developed Western countries, occurring in hospitals and long-term care facilities.<sup>1-4</sup> Infections involving the urinary tract, lungs, abdominal cavity, intra-vascular devices, surgical sites, soft tissues and subsequent bacteremia were the most common clinical syndromes. Recently these "classic" *K. pneumoniae* (cKP) strains have received increased notoriety due to their propensity for acquiring antimicrobial resistance determinants. As a result, treatment has become more challenging. The spread of New Delhi metallo- $\beta$ -lactamase (NDM-1)-containing strains from India associated with medical tourism and more recently the extreme drug-resistant *K. pneumoniae* outbreak at the Clinical Center Hospital on the National Institutes of Health campus have captured the attention of physicians, scientists and the lay press.<sup>5,6</sup>

A new hypervirulent variant of *Klebsiella pneumoniae* is emerging. In the mid-1980s and 1990s, reports from Taiwan described a unique clinical syndrome of community-acquired *K. pneumoniae* infections. Patients without a history of hepatobiliary disease presented with community-acquired pyogenic liver abscesses (CA-PLA) and a propensity for metastatic spread to distant sites.<sup>7-9</sup> Although these observations were initially made in the Asian Pacific Rim (e.g., Taiwan, Korea, Vietnam and Japan) an increasing number of cases are being reported from North America,<sup>10-17</sup> South America,<sup>18</sup> the Caribbean,<sup>19</sup> Europe,<sup>20-22</sup> the Middle East,<sup>23,24</sup> Australia,<sup>23</sup> Africa and South Africa.<sup>20,25</sup> A combination of clinical and bacterial phenotypic features have defined this new *K. pneumoniae* variant, which distinguishes it from cKP strains. The first is its ability to cause serious infection

\*Correspondence to: Thomas A. Russo; Email: trusso@acsu.buffalo.edu  
Submitted: 09/21/12; Revised: 10/29/12; Accepted: 10/30/12  
<http://dx.doi.org/10.4161/viru.22718>



**Figure 1.** Positive “string test” on a hypervirulent strain of *K. pneumoniae*.

in ambulatory, healthy hosts.<sup>15,20,25,26</sup> Unusual sites of infection have been observed, including endophthalmitis and meningitis. Further, it demonstrated an ability for metastatic spread of infection,<sup>7</sup> a common feature of certain Gram-positive pathogens such as *Staphylococcus aureus* and Streptococci, but uncommon for enteric Gram-negative bacilli (GNB) (e.g., extraintestinal pathogenic *Escherichia coli*, *Proteus* and cKP) in the absence of host compromise (e.g., neutropenia). Lastly, the appearance of colonies grown on an agar plate is hypermucoviscous. This phenotype (which does not necessarily equate to being mucoid) has been semi-quantitatively defined by a positive “string test.” The string test is positive when a bacteriology inoculation loop or needle is able to generate a viscous string > 5 mm in length by stretching bacterial colonies on an agar plate (Fig. 1). As a result of this latter phenotype, a number of reports have named this new variant as hypermucoviscous *K. pneumoniae*. However, taking all of its defining characteristics together, we believe that the use of the term hypervirulent *K. pneumoniae* (hvKP) is more appropriate. This descriptor takes into account its clinical features. Further, it remains unclear whether all hvKP are hypermucoviscous. Therefore in this review hvKP will be used and will encompass *K. pneumoniae* isolates with a positive string test and/or community-acquired *K. pneumoniae* infections with clinical features characteristic of hvKP such as metastatic spread.

Sequence typing is an increasingly utilized molecular epidemiologic approach for categorizing strains and a typing screen has been described for *K. pneumoniae*.<sup>27</sup> The repository for this data for *K. pneumoniae* is [www.pasteur.fr/mlst](http://www.pasteur.fr/mlst). Certain sequence types (ST) have been described for hvKP strains. ST23 has been most commonly described to date and is strongly associated with the K1 capsular serotype and liver abscess.<sup>20,23,28</sup> ST57 is also associated with the K1 serotype.<sup>29,30</sup> ST86, ST375 and ST380 are associated with the K2 serotype.<sup>20,31</sup> The complete genome sequence for the hvKP strain NTUH-K2044 (ST23, K1 capsular serotype) is in the public domain.<sup>32</sup>

### Pathogenesis of Infection

**How does acquisition/colonization with hvKP occur?** Presumably acquisition resulting in colonization is the first step necessary for subsequent endogenous hvKP infection.<sup>1</sup> However,

the incidence of infection in individuals colonized with hvKP and the time lag from acquisition to infection, if/when it develops, is unknown. Based on data from cKP and limited data from hvKP strains,<sup>33</sup> the GI tract appears to be the dominant site of colonization, with oro-pharyngeal or skin colonization being less frequent. A recent study from South Korea assessed for intestinal colonization with *K. pneumoniae* in 1,174 individuals.<sup>34</sup> A total of 248 KP isolates were obtained; 54 (4.6%) of which were ST23, which is strongly associated with, but not necessarily diagnostic of, hvKP strains. Intestinal colonization with ST23 strains was greater in those > 25 y of age and lower in Koreans who had lived abroad. Another study assessed the seroepidemiology of 592 *K. pneumoniae* strains isolated from stool specimens obtained from 954 healthy Chinese adults who were residents of Taiwan, Hong Kong and China or living abroad in Japan, Thailand, Malaysia, Singapore and Vietnam.<sup>35</sup> Overall, 39 (4%) and 19 (2%) of individuals were colonized with a K1 or K2 serotype of *K. pneumoniae* respectively. Although the K1 and K2 capsular serotypes are common in hvKP strains, cKP strains may also possess these serotypes,<sup>29</sup> and hvKP strains may have a non-K1/K2 serotype.<sup>26,36-38</sup> Despite the stated limitations, these data strongly suggest that a certain percentage of Asians are colonized with hvKP strains. These data also support the concept that colonization is requisite for, but does not necessarily lead to, infection.<sup>34,35,39</sup>

Still, the means of hvKP acquisition remains undefined. Data from other Enterobacteriaceae, such as *E. coli* and cKP, would suggest that the vehicle(s) for acquisition and subsequent colonization are some combination of food, water, person-to-person transmission (e.g., close contacts such as family members or sexual partners) and animal-to-person transmission (e.g., between pets and their owners).<sup>40</sup> Data on hvKP is limited. A report demonstrated that a healthy father and his son developed primary liver abscess at different times and the wife/mother had asymptomatic intestinal colonization with the same hvKP strain (ST23, K1 serotype).<sup>39</sup> However, it is impossible to tell whether colonization of each family member was from a common food/water source or person-to-person transmission. It is reasonable to consider travel to the Asian Pacific Rim or exposure to people from that area as a risk factor for hvKP infection. Acquisition leading to colonization and subsequent infection from International travel has been documented for Enterobacteriaceae, including cKP and hvKP.<sup>15,21,41</sup> Nevertheless, this risk factor has not been observed in all cases acquired outside of Asia.<sup>10,11,20</sup> Although hvKP infection primarily occurs in ambulatory patients, acquisition in a health-care facility also has been described.<sup>42</sup> Further, given the innate virulence of hvKP, acquisition in patients with co-morbidities (e.g., cancer) may result in severe disease. Therefore, contact with healthcare workers or inanimate objects within the facility are possible mechanisms of acquisition and consideration should be given for appropriate infection control measures.

**What is the mechanism for hvKP entry into the extraintestinal site of infection?** Entry into an extraintestinal organ or site is the next critical step in pathogenesis. But, the mechanism by which this occurs for hvKP is a mystery. Mechanisms for cKP and other Enterobacteriaceae include ascension into the bladder from the perineum, disruption of the bowel enabling entry of

GI tract colonizers into the peritoneal cavity, micro- or macro-aspiration of oro-pharyngeal colonizers into the respiratory tract or disruption or breakdown of the skin barrier. However, infection with hvKP usually occurs in persons who do not have overt disruptions of these host barriers to infection.

Although the mechanism of entry in humans has not been established, several considerations seem most plausible at this point. In patients who present with pneumonia, it is certainly conceivable that oro-pharyngeal colonization followed by micro- or macro-aspiration leads to pneumonia. Although some patients with hvKP appear to present with aspiration-mediated pneumonia,<sup>43</sup> the primary site of infection is most often outside of the lungs.<sup>4,42</sup>

Given the common presentation of pyogenic liver abscess (PLA), the ability to invade across an intact intestinal mucosa, which occurs with *Salmonella* Typhi or ascension up the biliary tree are plausible routes. But, the usual lack of biliary tract disease, a hallmark feature of patients with hvKP-mediated PLA, makes that route less likely. A recent report did demonstrate concurrent intestinal and/or pharyngeal colonization with hvKP in 35/43 and 17/43 patients respectively with PLA.<sup>33</sup> Liver aspirate-fecal-saliva hvKP isolates from the same patient were identical or closely related by pulsed field gel electrophoresis in all 17 instances evaluated.<sup>33</sup> These data suggest, but do not establish, an intestinal route of entry. Mouse models of hvKP infection support the possibility of invasion across the intestinal mucosa.<sup>44</sup> Nevertheless, if intestinal invasion can occur in humans, we are left with a question as to why there are a number of individuals with intestinal colonization who do not develop infection. Prior immunity to hvKP, a lower degree of colonization or variable efficiency of invasion across the intestinal mucosa are potential explanations. Alternatively, this observation also suggests that entry may occur from a non-intestinal focus.

Entry through an overt or occult break in the skin resulting in bacteremia, similar to what occurs in some cases of invasive *Staphylococcus aureus* infection,<sup>45</sup> is another possibility, albeit conjectural. In many cases, it is difficult to distinguish the primary site of infection from sites of subsequent spread. In fact, it is likely that a number of cases with multiple organs/sites are seeded from the initial bacteremia. Of interest, to date, no cases of laboratory acquisition have been described. Most likely, a variety of entry sites can lead to hvKP infection.

**hvKP factors that contribute to intestinal colonization/invasion have been identified.** Using mouse infection models a number of factors important in cKP colonization have been identified, which include capsular polysaccharide (CP),<sup>46</sup> lipopolysaccharide (LPS), fatty acid and phospholipid synthesis, outer membrane protein (OMP) A, OMP and DNA folding proteins, a protein synthesis elongation factor, an aerobic-anaerobic metabolism regulator, hypothetical proteins,<sup>47</sup> a high molecular weight adhesion, O-sialoglycoprotein endopeptidase, lactose metabolic enzyme, cyclohexadienyl dehydratase,  $\alpha$ -glucan phosphorylase, amide-urea binding protein, harpin type III secretion system, DNA primase, adenine-specific methylase, nitrogen and glycine metabolism regulators and a hypothetical protein.<sup>48</sup>

A number of hvKP genes have also been implicated as important for intestinal colonization and/or possible invasion across

the intestinal barrier in mouse models, but some studies do not experimentally distinguish between these two possibilities. Using a signature tagged approach, 28 mutants were identified as having decreased growth/survival in liver and spleen samples after intra-gastric (IG) challenge.<sup>44</sup> Eight of these, a putative type III fimbrial usher protein (*mrkC*), a uracil permease (*kva28*), a two-component regulator system (*kvgA-kvgS*, which has been shown to contribute to capsule formation),<sup>49</sup> a monamine regulon positive regulator (*moaR*), a LuxR family transcriptional regulator (*kva15*) and two hypothetical proteins (*kva7,21*), when individually tested, caused no mortality after IG challenge, compared with 100% for their wild-type parent hvKP strain CG43 (ST86, K2 serotype). Yet they were as lethal as CG43 after intraperitoneal (IP) challenge, demonstrating that these mutations inactivated genes important for intestinal colonization and/or invasion.

Kfu, which mediates uptake of ferric iron, is more prevalent in hvKP compared with cKP strains and was shown to be a factor for virulence in mice after IG but not after IP challenge.<sup>50,51</sup> Although the possibility that Kfu is a factor for invasion cannot be excluded, its function supports a role as an intestinal colonization factor since free ferric iron is available within the intestinal tract, but not within the host. Likewise, allantoin metabolism genes, which enable nitrogen assimilation from purine catabolism or exogenous allantoin have been shown to be present more frequently in hvKP strains with a K1 serotype, but not with hvKP K2 or non-K1/K2 serotypes, when compared with cKP strains.<sup>29,38,52</sup> These genes were also shown to contribute to virulence in mice after IG challenge but not with IP challenge.<sup>52</sup> Although a role in invasion cannot be excluded, a role in colonization is biologically more plausible given their function. Still, the absence of these genes in non-K1 hvKP strains raises the issue of their relative importance in hvKP infection.

Lastly, by using an intestinal competition assay in mice, deletion of the trehalose utilization gene *treC* in the hvKP strain NTUH-K2044 resulted in decreased capsule production, biofilm formation, and intestinal colonization.<sup>53</sup> Likewise, disruption of *celB*, whose product participates in the transport of cellobiose across the cytoplasmic membrane, resulted in decreased biofilm formation, intestinal colonization, and mortality after IG challenge.<sup>54</sup> It remains unclear whether the decreased mortality was due to a difference in colonization, invasion or extraintestinal virulence. Nonetheless, these data established that for NTUH-K2044 biofilm formation promotes intestinal colonization, a critical step in the pathogenic process.<sup>53,54</sup> Although NTUH-K2044 was also shown to produce more biofilm than cKP strains,<sup>53</sup> the relative role of this increased biofilm production for intestinal colonization in hvKP strains compared with cKP strains is not yet clear.

**The ability for hvKP strains to grow/survive post entry is greater than for cKP isolates.** Entry alone does not necessarily result in infection. The bacteria must be able to survive and proliferate in the face of the host defenses. This is achieved by some combination of the infecting inoculum, the inherent virulence of the bacterial strain and the status of the host. For example, a higher inoculum or compromised host may enable infection with a less virulent strain. By contrast, hvKP is a professional

pathogen as defined by its ability to cause serious infection in a normal host. Therefore, one would predict a lower inoculum to cause disease. Although this has not been established in humans, both in vitro and animal model data support this concept. In a rat subcutaneous abscess model, the growth/survival of the hvKP strain hvKP1 is significantly greater than all 4 cKP bacteremic isolates tested.<sup>15</sup> Similarly, an increased mortality was observed after intra-venous challenge in mice with hvKP strains compared with cKP strains.<sup>25</sup>

Further, hvKP appears to be an extracellular bacterial pathogen. A defining virulence feature in these organisms is the ability to resist the bactericidal activity of antimicrobial peptides, and complement and phagocytes in the absence of antibody. hvKP1 was shown to be significantly more resistant to the complement-mediated and neutrophil-mediated bactericidal activity than four of four and three of four bacteremic cKP isolates, respectively.<sup>15</sup> Taken together, this body of data support that hvKP strains are more virulent than cKP strains.

**What are the mechanism by which hvKP is able to grow and survive within the host? Do some of these mechanisms explain the enhanced virulence of hvKP compared with cKP?** The ability of microbial pathogens to modify their inherent virulence or pattern of spread is part of the evolutionary process of host-pathogens interactions. Most commonly, this occurs by horizontal (lateral) gene transfer via bacteriophage, plasmids, or transposons. Pathogenicity islands and virulence plasmids are common examples of this mechanism. Virulence can also be enhanced via loss of function or point mutations in critical genes (e.g., regulatory genes). Clearly, there has been a modification of the hvKP phenotype. Yet, an incompletely answered question is what are the mechanisms responsible for this change that has made this variant far more virulent than cKP strains, from which it presumably evolved. Virulence plasmid acquisition may be an important mechanism for the increased virulence of hvKP. Genes that encode a number of virulence factors, including those that are responsible for the hypermucoviscous phenotype (RmpA) and iron-acquisition factors (aerobactin and salmochelin) are located on a large, 180–220 kb virulence plasmid that is not present in most cKP strains.<sup>38,55,56</sup>

Multiple factors are required for virulence with hvKP being no exception. Epidemiologic and comparative genomic studies are an important means to identify candidate virulence factors. However ultimately, biologic studies assessing isogenic mutants are requisite. Further such studies need to be performed in a model that employs a clinically relevant route of entry and results in disease representative of hvKP infection. To date, models have utilized IG, sub-cutaneous, peripheral intravenous and IP routes of entry and infection of a pre-formed sterile abscess. Although the route of entry has not yet been defined for hvKP, peripheral intravenous and IP routes would appear to be less relevant. In addition, most studies have focused on whether a given factor that is often also present in cKP contributes to hvKP virulence. More experiments are needed to establish whether a virulence factor or property present in both cKP and hvKP is equally important for their pathogenesis or whether it accounts for the increased virulence of hvKP strains compared with cKP strains.<sup>57</sup>

**Iron acquisition.** The ability to acquire iron is essential for bacterial growth and replication. This trait has been shown to play crucial role in the progression of infection, including cKP.<sup>58</sup> The host has a number of iron-binding proteins (e.g., transferrin) that serve to withhold iron from the invading pathogen. In turn, to acquire iron from the host's iron-binding proteins, *K. pneumoniae*, like other Enterobacteriaceae produces siderophores. These small molecules are secreted, "steal" iron from the host due to their higher affinity than host binding proteins and then re-enter the bacterial cell by siderophore-specific receptors.<sup>59</sup> Aerobactin, enterobactin, salmochelin and yersiniabactin are siderophores that have been described in *K. pneumoniae*.<sup>50</sup>

Non-comprehensive data on which iron acquisition elements are present in cKP vs. hvKP strains exists. Gene clusters for the yersinia high pathogenicity island (encodes for yersiniabactin) and *iucABCDiutA* (encodes for aerobactin and its cognate receptor) were more prevalent in hvKP (38/42 and 39/42 respectively) than cKP (7/32 and 6/32 respectively).<sup>50</sup> In addition, aerobactin production, as demonstrated by a cross-feeding assay, was more common in hvKP strains than cKP strains.<sup>25</sup>

These bioinformatic-molecular epidemiologic analyses suggested that hvKP strains might have the capability to acquire iron more readily than cKP strains. Hsieh et al. began to address this possibility by assessing the virulence of mutant derivatives of the hvKP strain NTUH-K2044 in which the capability to synthesize yersiniabactin (*irp*), aerobactin (*iuc*) and salmochelin (*iro*) were abrogated either alone or in combination.<sup>50</sup> Mutant derivatives in which *irp*, *iuc* or *iro* were disrupted alone were as virulent as their wild-type parent after IP challenge. A decrease in virulence after IP challenge was only seen when *irp*, *iuc* and *iro* were disrupted together. Likewise, disruption of *tonB*, which encodes for a protein requisite for uptake of siderophores, hemin and ferric citrate resulted in decreased virulence as well. These data established that iron acquisition was needed for optimal systemic virulence of hvKP. Still, disruption of multiple iron-acquisition systems was needed before a decrease in hvKP's virulence was observed. Therefore, the inference from these data is that the acquisition of genes that enable aerobactin or yersiniabactin synthesis and uptake alone do not enhance pathogenicity. Perhaps the acquisition of a combination of these iron-acquisition systems contributes to the increased virulence of hvKP.

Recent data, however, has established that not only is iron-acquisition a critical virulence trait for hvKP, but that it is accomplished more efficiently than cKP.<sup>57</sup> The hvKP strain hvKP1 (ST86, K2 serotype) produced more iron-acquisition factors (likely siderophores) than four cKP bacteremic isolates. Further, it was shown that this property enhanced the resistance of hvKP to complement-mediated bactericidal activity in vitro. Most importantly, this trait enabled a significant increase in growth/survival in human ascites ex vivo and in vivo in a mouse model of metastatic infection for hvKP compared with cKP.<sup>57</sup> Therefore, this study established that the ability of hvKP to produce more iron acquisition factors enhanced its virulence. This observation is a critical observation and is the first clear example of why hvKP is more virulent than cKP. The mechanism responsible for this phenotype is under investigation.

*Surface polysaccharides.* GNB in general, including hvKP, possess an extracytoplasmic outer membrane. This outer membrane consists of a lipid bilayer with associated proteins, lipoproteins and polysaccharides. The outer membrane interfaces with the bacteria's environment, including the human host. Therefore its components are often critical determinants in pathogenesis.

*Hypermucoviscous phenotype.* A distinguishing factor of hvKP strains is its hypermucoviscous phenotype. The vast majority, but not all of the strains that cause CA-PLA possess this phenotype.<sup>38</sup> An initial study that investigated its nature reported that it was distinct from the constitutive K2 capsule and the surface polysaccharide colanic acid.<sup>60</sup> However, subsequent investigators have reported that it represented an increased amount of capsular material with the same components as the constitutive capsule. Whether this increased amount of polysaccharide represents an increase in the amount of the constitutive capsule<sup>36,61</sup> or whether it is an extracapsular polysaccharide (exopolysaccharide) that is physically distinct but biochemically the same as the constitutive capsule remains contested.<sup>62</sup>

The factor that mediates the expression of the hypermucoviscous phenotype is RmpA/RmpA2 (regulator of the mucooid phenotype). Three genes that are variably present in hvKP strains have been reported to encode for RmpA/RmpA2: a chromosomally located *rmpA*, *rmpA* present on a plasmid and *rmpA2*, which is also located on a plasmid. In one study, 9/48 hvKP strains possessed all three genes, 35/48 possessed p-*rmpA*/p-*rmpA2*, 3/48 possessed only p-*rmpA* and 1/48 possessed c-*rmpA* alone.<sup>36</sup> However, some cKP strains may also possess *rmpA/rmpA2*. Based on its GC content and the presence of a 5'-located IS3 insertion sequence, *rmpA2* appears to have been acquired, at least in some instances by horizontal acquisition.<sup>62</sup> In CG43 both p-RmpA and p-RmpA2 increase the expression of capsule genes and the hypermucoviscous phenotype, whereas in NTUH-K2044 only p-RmpA, but not c-RmpA or p-RmpA2, do so. Hopefully, future studies in other backgrounds will clarify the roles of each RmpA in mediating mucoviscosity. For clarity, the gene *magA* was initially reported as the mediator of the hypermucoviscous phenotype, but has since been clarified as being the K1 specific capsular polymerase gene (*wzy\_K1*).<sup>26,63</sup>

Although the mechanism by which RmpA/RmpA2 mediates mucoviscosity is still being investigated, details are emerging. RmpA (in CG43 and NTUH-K2044) and RmpA2 (in CG43, but not NTUH-K2044) are positive regulators of capsule synthesis by binding to the regulatory 5' region of capsule genes.<sup>61,64</sup> It appears that RmpA/RmpA2 act in a fashion similar to RcsA. RcsA, along with RcsB-D and Lon protease are part of a regulatory system for the synthesis of the surface polysaccharide colanic acid in *E. coli*.<sup>65</sup> RmpA/RmpA2, similar to RcsA/RcsB are part of the UhpA-LuxR transcriptional regulator family. However, a critical difference is that RmpA/RmpA2 are active at 37°C, whereas RcsA is degraded by Lon at this temperature and is much more active at lower, non-physiologic temperatures.<sup>61</sup> Similar to RcsA, RmpA is dependent on and interacts with RcsB. Further, *rmpA* and *rmpA2* expression is negatively regulated by Fur.<sup>66</sup> The inference from this observation is that mucoviscosity would increase in an iron-depleted state, such as the human host.

In hvKP strains the *rmpA/rmpA2* genes are often present on a large, approximately 180–220 kb virulence plasmid that contains other factors that may contribute to virulence. Therefore, interpretation of molecular epidemiologic, plasmid loss/gain studies, or comparison studies using strains with different genetic backgrounds designed to assess the role of RmpA/RmpA2 and/or the hypermucoviscous phenotype are difficult to interpret.<sup>38,60,67</sup> Studies that have assessed the virulence of isogenic mutant in infection models present conflicting results. In the genomic background of the hvKP strain CG43, p-*rmpA* has been shown to add to the virulence of the hvKP strain in a mouse IP challenge model.<sup>61</sup> By contrast, in the background of NTUH-K2044 disruption of c-*rmpA* and p-*rmpA* did not affect its virulence in mouse IG or IP challenge models.<sup>36</sup> Additional studies in other strains are needed to clarify the roles of each RmpA in mediating virulence.

*Capsular polysaccharide (CP).* At least 78 CP serotypes exist in *K. pneumoniae*.<sup>68</sup> The capsule, especially serotypes K1 and K2, has long been known to be an important virulence factor in cKP. This effect is mediated in part by conferring an increased resistance to complement, antimicrobial peptides, and professional phagocyte-mediated bactericidal activity.<sup>69-73</sup>

For hvKP strains, eight capsular serotypes have been described to date; K1, K2, K5, K16, K20, K54, K57 and the new capsular serotype KN1.<sup>68,74,75</sup> Further, the co-existence of *rmpA/rmpA2* is extremely uncommon in serotypes other than these (1/117).<sup>36</sup> In hvKP strains the prevalence of K1, K2 and non-K1/K2 serotypes has ranged from 47–81%, 20% and 23–33% respectively.<sup>26,36-38,76</sup> Because the majority of hvKP strains that caused CA-PLA were either a K1 or K2 serotype, these capsular serotypes were initially believed to be the critical virulence factor in this infectious syndrome.<sup>26,37</sup> However, up to 1/3 of hvKP strains possess non-K1/K2 serotypes.<sup>26,36-38</sup> Further, since cKP strains that possess K1 and K2 serotypes were significantly less virulent in a mouse infection model,<sup>29</sup> the presence of a K1 or K2 serotype alone does not confer Klebsiella with a hypervirulent phenotype. Therefore, although capsule is a pathogenesis factor, it seems likely that the high level of virulence observed in hvKP strains is due to an increased expression of capsular material (hypermucoviscous phenotype) in combination with an increased efficiency of iron-acquisition and other traits that remain undefined.

*Lipopolysaccharide (LPS).* LPS consists of lipid A, which is essential in most GNB, a core region, and an O-antigen that consists of repeating polysaccharide units that confers serotype-specific antigenicity. Eight to 12 LPS serotypes have been described in *K. pneumoniae*.<sup>77</sup> The bulk of, but not all, data supports LPS being an important virulence factor in cKP.<sup>72,78-80</sup> The O1-antigen LPS moiety has also shown to be an important virulence factor in mouse infection models in the hvKP strain NTUH-K2044,<sup>81</sup> which was mediated, at least in part, by conferring resistance to complement mediated bactericidal activity. No data are available on whether LPS contributes in some manner to the increased virulence of hvKP strains.

*Adhesins.* Both cKP and hvKP possess type 1 (mannose-sensitive) and type 3 (mannose resistant) fimbriae. In cKP strains

these fimbriae have been shown to adhere to host epithelial cells from the respiratory and urinary tracts and add to infection.<sup>82,83</sup> Although little work has been done on hvKP, a recent study examined the regulation of type 3 fimbriae in the hvKP strain CG43.<sup>84</sup> This study confirmed observations that type 3 fimbriae contribute to biofilm formation as well as demonstrating that expression positively correlated with iron concentration. Although in vivo virulence was not addressed, these data suggest that type 3 fimbriae are less likely to be important within the human host where free iron is limited. The gene *cf29A*, which encodes the adhesin CF29K, has been described in both cKP and hvKP strains. But in one study it was more strongly associated with hvKP strains.<sup>29,85</sup> We are unaware of any in vivo data designed to assess CF29K as a virulence factor.

**Biofilm formation.** A bacterial biofilm consists of an aggregate of cells contained within a matrix of surface polysaccharides, proteins and DNA. The ability to produce a biofilm results in enhanced resistance to host defense factors and antimicrobials and is being increasingly recognized as an important virulence property.<sup>86,87</sup> Even in the absence of a foreign body, biofilm formation has been shown to be a factor in closed-space infections.<sup>88-90</sup> In vitro studies have established that cKP strains are able to produce biofilm, with type 3 fimbriae,<sup>91,92</sup> CP and LPS,<sup>93,94</sup> amino acid synthesis genes,<sup>95</sup> L-arabinose metabolism,<sup>95</sup> sugar phosphotransferase systems,<sup>94</sup> the type 2 quorum sensing regulatory system,<sup>94</sup> the Lys-R-type regulator oxyR<sup>96</sup> and a putative cell surface protein<sup>95</sup> identified as contributory factors. The hvKP strains NTUH-K2044 and KpL1 have also been shown to produce biofilm with putative gene products similar to those factors identified in cKP being contributory.<sup>53,97</sup> These included CP, LPS, pilin, carbohydrate transport and metabolism and type 2 quorum-sensing genes. Studies on the hvKP strain hvKP1 identified the genes that putatively encoded glutamine synthetase, succinyl-CoA synthase  $\alpha$  subunit and a transcriptional antiterminator of glycerol uptake operon as being contributory to biofilm formation.<sup>98</sup>

An important observation by Wu et al. was that hvKP strains produced more biofilm than cKP isolates, thereby suggesting that biofilm formation may be a contributing factor to its increased virulence.<sup>53</sup> Although the mechanism(s) responsible for increased biofilm formation in hvKP strains has not yet been defined, the role of biofilm formation for the hvKP strain NTUH-K2044 in promoting intestinal colonization has been discussed (please see the section “hvKP factors that contribute to intestinal colonization/invasion have been identified”). Although it is logical, it is still unclear whether biofilm formation plays a direct role in extraintestinal hvKP infection. Mutant derivatives of the hvKP strain hvKP1 that produced less biofilm were equally resistant to complement mediated bactericidal activity and their growth and survival in a rat subcutaneous abscess model was similar to their wild-type parent.<sup>98</sup> Nonetheless, these studies do not exclude a potential effect of biofilm in the other phases/aspects of systemic infection (e.g., metastatic spread).

**Do host factors affect the susceptibility to developing hvKP infection?** A predilection for infection in Asians has been seen,<sup>9,42</sup>

which poses a question of host genetic susceptibility vs. geographically defined pathogen exposure and acquisition. Although infections have been described in a variety of ethnic groups, even those acquired in Western countries commonly occur in Asians.<sup>11-18,20-22</sup> The breakdown of ethnic groups from 35 cases of hvKP infection reported from Western countries was: Asians 20 (including Filipinos), Africans 6, Caucasians 6, Hispanics 1 and not reported 2.<sup>11-13,15,17,19-22</sup> Of course this does not establish a genetic risk for infection since Asians infected in the West may have traveled to or been exposed to individuals who had recently been in the Asian Pacific Rim, which in turn lead to acquisition of hvKP.<sup>15</sup> In fact, a case from Denmark in a Caucasian who traveled to Shanghai, China suggests this very scenario.<sup>21</sup>

Diabetes mellitus (DM) has long been recognized as a disease predisposing to bacterial infections. Ever since the recognition of hvKP infection, DM has been speculated as a significant risk factor. The majority of studies have determined this to be the case,<sup>4,7,9,99-103</sup> although others did not conclude that DM was an independent predictor for hvKP infection.<sup>25,42</sup> It is critical to note that hvKP infection is seen in all age groups and despite the fact that some patients have co-morbidities, it is frequently seen in younger, healthy patients. DM or any other co-morbidities are not requisite for the development of this potentially devastating disease.

## Clinical Disease

**A comprehensive understanding of the prevalence and spectrum of hvKP disease is lacking due to the lack of an objective diagnostic test.** The lack of an unequivocal genotypic/phenotypic marker(s) for hvKP has precluded a comprehensive understanding of the prevalence and spectrum of hvKP disease. Although a positive “string test,” which reflects the hypermucoviscous phenotype, is the best laboratory-based surrogate marker presently available, as mentioned above it is unclear whether all hvKP strains possess this trait. Further, this test is not routinely performed in clinical laboratories. In addition, the clinical features that characterize hvKP infection are likewise not broadly appreciated. As a result, the incidence of hvKP infection and the clinical spectrum of disease are almost certainly underappreciated. In a number of reports describing *Klebsiella* infection, information on the characteristics needed to assist in differentiating between cKP and hvKP are lacking. Therefore in this review, infectious syndromes due to *K. pneumoniae* isolates with a positive string test and/or community-acquired *K. pneumoniae* infections with clinical features characteristic of hvKP such as metastatic spread will be attributed to hvKP.

**The resultant morbidity and mortality from hvKP infection is significant.** Despite the fact that the majority of patients with hvKP infection are younger and do not have co-morbidities, it is still associated with a significant mortality rate, ranging from 3 to 42%.<sup>4,9,20,26,99,104,105</sup> Remarkable mortality rates of 55% for community-acquired pneumonia with bacteremia<sup>43</sup> and of 47% for necrotizing fasciitis<sup>75</sup> have been seen. Further, survivors with infection in critical sites often suffer catastrophic morbidity such as loss of vision, neurologic sequelae, or loss of limb.<sup>7,8,26,75,99</sup>


**Sites of infection. Abdominal disease. CA-PLA.** Prior to the 1980s, *E. coli* was the most commonly isolated enteric GNB from PLA in the Asian Pacific Rim; usually in the setting of biliary disease and often co-isolated with other pathogens such as anaerobes. But more recently, hvKP has emerged as the dominant cause of PLA. The rate of PLA has increased steadily in Taiwan from 1996 (11.15/100,000) to 2004 (17.59/100,000).<sup>106</sup> In Korea, from 2004–2005, 78% of cases were caused by hvKP with 59% of the hvKP isolates having a K1 serotype.<sup>76</sup> Likewise in Taiwan, approximately 4,000 cases were reported in 2004 with approximately 80% being due to hvKP having a K1 serotype,<sup>50</sup> and from 2005–2008, > 3,000 cases were reported annually.<sup>33</sup> In Western countries, there seems to be an increase in the number of cases of PLA due to *K. pneumoniae*. Two small series reported that *K. pneumoniae* was the responsible pathogen in 36% and 41% of cases, albeit the exact number of cases due to hvKP is unclear.<sup>14,107</sup> In these reports, 70% of affected patients were Asian, but travel histories or close contact with recent travelers to the Asian Pacific Rim were not optimally delineated. Therefore, it is unclear what percent of these cases were imported vs. endogenous. Nonetheless, it is clear that an increasing number of cases of CA-PLA due to hvKP are present in various Western countries and an awareness of this entity, which may be complicated by severe sepsis or metastatic infection is needed.<sup>10-13,15,20,22,108</sup>

Primary PLA in ambulatory patients without biliary disease was the defining syndrome that led to the recognition of hvKP.<sup>7-9</sup> As described above, although the means of hepatic seeding is unclear, it likely occurs hematogenously via the portal or perhaps systemic circulation. hvKP-mediated PLA is almost always mono-microbial. Except for the potential co-incidental presence of metastatic complications and usually a normal biliary tract, the clinical and laboratory presentation of hvKP-mediated PLA is not significantly different from other causes of PLA. However, a somewhat anecdotal but interesting feature that warrants further examination is a number of reports of reinfection/relapse at the same or different site, sometimes with the same strain, months to greater than a year after the end of therapy.<sup>9,10,39,109</sup>

**Splenic abscess.** This can be a primary or metastatic site of infection. *K. pneumoniae* was the first or second most common pathogen responsible for splenic abscess in recent series from Korea and Taiwan.<sup>110-112</sup> The presence or absence of a hypermucoviscous phenotype was not reported in these series. Nevertheless, a number of patients had concomitant PLA or metastatic spread at another site. Since *K. pneumoniae* is an exceedingly rare cause of splenic abscess in adults, it is likely that hvKP was the responsible pathogen.

**Spontaneous bacterial peritonitis.** Although hvKP infection has not been explicitly described to occur in the setting of hepatic cirrhosis with attendant portal hypertension and ascites,<sup>4,42</sup> this must be the case since it has been described as a cause of spontaneous bacterial peritonitis.<sup>42</sup>

**Thoracic disease. Pneumonia.** Although cKP is a relatively common cause of healthcare-associated pneumonia in the West, over the last several decades, *K. pneumoniae* has been an exceedingly rare cause of community-acquired pneumonia (CAP) in North America, Europe and Australia.<sup>4,113</sup> By contrast, it is an important



**Figure 2.** Endophthalmitis as the presenting symptom for hypervirulent *K. pneumoniae* infection in a previously healthy 33-year-old male.

cause of severe CAP associated with bacteremia in South Africa and Taiwan. Sixty-seven percent (33/49) of patients with CAP were due to hvKP strains and 94% of these affected individuals were younger patients with no underlying disease.<sup>4,25</sup> A more recent study that assessed all cases from 2001 to 2008 reported that bacteremic hvKP CAP accounted for 31% (46/148), just slightly more than *S. pneumoniae*.<sup>43</sup> Importantly, when compared with *S. pneumoniae*, hvKP infected patients experienced a higher mortality (55.1% vs. 27.3%) with, not surprisingly, septic shock and respiratory failure being independent predictors of death. In primary CAP due to hvKP, airspace disease, which is frequently bilateral or lobar disease is the usual radiographic pattern.<sup>43</sup> This contrasts with pulmonary infection due to hematogenously mediated metastatic spread (e.g., liver abscess via the hepatic vein) where nodular, usually bilateral densities are seen that are more common in the lower lobes. In both pathophysiologic patterns cavitation (necrosis) can occur.

**Empyema/complicated parapneumonic effusion.** As would be expected in geographic regions with a high incidence of hvKP CAP, *Klebsiella pneumoniae* (characteristics to differentiate cKP from hvKP not always determined) is a leading or the most common cause of empyema.<sup>114-116</sup> Although the majority of pleural space infections are due to a pneumonia, spread from a contiguous abdominal source (e.g., PLA) or hematogenous seeding from a distant site may occur.

**Endophthalmitis.** This devastating complication of hvKP infection, when first described in 1986, was one of the first hints that something was different with the *K. pneumoniae* isolates responsible (Fig. 2).<sup>8</sup> Endogenous endophthalmitis (EE), which occurs via hematogenous dissemination, is much less common than exogenous endophthalmitis, which results from trauma or surgery. EE due to enteric GNB was an uncommon infection in ambulatory, healthy hosts until the advent of hvKP and may occur as a primary or metastatic infection. Patients with PLA have 0.83–11% risk of developing EE.<sup>7,9,117-120</sup> 4.8% patients with hvKP bacteremia developed EE.<sup>42</sup> Painful ocular

swelling, redness and the sudden onset of blurred vision are most common symptoms. On examination, hypopyon and increased intraocular pressure may be seen. Bilateral involvement occurs in 13–25% of patients.<sup>119,121-123</sup> EE may be the presenting manifestation of hvKP infection, occurring as such in 45% of cases in one report.<sup>119</sup> Prognosis even with aggressive treatment is dismal, with poor vision and blindness being the rule. Still, early recognition and treatment for one eye may prevent a worse outcome from occult infection in the other.<sup>8,119,121,124</sup> This is attributable to the virulence of hvKP and delayed recognition.

**Central nervous system disease. Meningitis.** The face of community-acquired meningitis has changed in Southeast Asia over the past 30 y<sup>125</sup> and is at risk of changing beyond the Asian Pacific Rim as hvKP spreads across the globe. Alarming, *K. pneumoniae* has become a major cause of community-acquired meningitis in Asia in the absence of neurosurgery or head trauma;<sup>125-128</sup> a remarkable infection in healthy, ambulatory adults and almost unheard of in the West<sup>129</sup> until recently.<sup>14</sup> Although not all of the responsible strains were characterized and established to be hvKP in the cited reports, a number have been.<sup>14,20,25,42</sup> These cases, combined with the coincidental spread of hvKP through the Asian Pacific Rim, strongly implicate hvKP as being responsible. Meningitis may be the presenting primary infection or secondary to metastatic spread.<sup>130</sup>

**Other CNS infections.** In addition to meningitis, alone or in combination brain abscess, subdural empyema, and epidural abscess have been described.<sup>19,131-133</sup>

**Musculoskeletal and soft tissue infection.** hvKP has become a common cause of necrotizing fasciitis in Taiwan, causing a similar number of cases as group A streptococcus and having a higher mortality (47% vs. 19%).<sup>75</sup> It also has been described outside of the Asian Pacific Rim.<sup>21</sup> Psoas abscess,<sup>7,109,134</sup> deep neck infection,<sup>11,16,17</sup> osteomyelitis<sup>7,13,109</sup> and septic arthritis<sup>7,109</sup> have all been described and may be the presenting site of infection. Recurrent soft-tissue infection at different sites has also been described.<sup>109</sup> Discitis, vertebral osteomyelitis, and paraspinal abscess may occur in conjunction with an epidural abscess as described above.<sup>132,133</sup>

**Urinary tract.** Although the ascending route is the most common mechanism for the development of urinary tract infection (UTI) in general as well as for cKP, this may not be the case for hvKP. Although the urinary tract is cited as a source of hvKP bacteremia,<sup>42</sup> we have been unable to identify any reports on ascending UTI, despite the plausibility of this route with hvKP being an intestinal colonizer. Bacteremic spread to the kidneys, perinephric region, and prostate resulting in abscess formation are well described.<sup>78</sup> Although additional data are needed, perhaps we should consider the presence of hvKP in the urine as a potential marker for bacteremia, similar to *S. aureus*.<sup>135</sup>

**Miscellaneous.** Nearly every site in the body has been infected with hvKP. A few less common sites include orbital cellulitis,<sup>136</sup> mediastinitis<sup>11</sup> and a Bartholin abscess.<sup>137</sup>

**Bacteremia/endovascular.** Bacteremia is an extremely common complication of hvKP site-specific infection. In one report in which bacteremic isolates were established to be hvKP strains by a positive “string test,” infected foci included PLA (32.5%), pneumonia (20.5%), urinary tract (10.8%), biliary tract (8.4%),

soft-tissue (6%), meningitis (4.8%), empyema (4.8%), spontaneous bacterial peritonitis (2.4%) and endophthalmitis (1.2%).<sup>42</sup> Primary bacteremia was observed in 22.9% of cases. Interestingly, 14.8% of hospital-acquired *K. pneumoniae* bacteremias were due to hvKP strains.

A case of native valve endocarditis<sup>138</sup> due to hvKP as well as a case of Lemierre syndrome (septic internal jugular venous thrombophlebitis),<sup>139</sup> likely due to hvKP, have also been reported.

## Treatment of hvKP Infection

Compounding an already challenging clinical situation is the recent propensity for cKP to become multi-, extreme or pan-drug-resistant, including the acquisition of extended-spectrum  $\beta$ -lactamases and carbapenemases, such as the recently described NDM-1.<sup>5,140</sup> To date, most strains of hvKP have been very susceptible to antimicrobials except ampicillin.<sup>26,43</sup> Nonetheless, some cases of infection due to MDR-hvKP have already been described<sup>75,141</sup> and as expected, outcome is worse with inappropriate treatment.<sup>100</sup> As a result, management of infections due to hvKP will become extremely challenging, and morbidity and mortality rates will further increase. The confluence of hypervirulence and extreme or pan-drug resistance in hvKP has the potential to create a “post-antibiotic” scenario; similar to what was feared with methicillin-resistant *S. aureus*, which was never realized. hvKP strains may be the next “superbugs” in waiting.

A basic tenet of infectious diseases is the need to drain abscesses/closed space infections for optimal outcome. Since hvKP strains often cause abscesses, source control is a major aspect of the overall management plan. In the present era of interventional radiology and percutaneous drainage of accessible abscesses, open surgical drainage occurs uncommonly. However, the physical property of hypermucoviscosity possessed by hvKP may make catheter drainage challenging. Although we are unaware of any studies that have addressed this issue, open drainage may need to be considered in select cases.

## A Large Number of Knowledge Gaps on hvKP Exist

Enhancing our understanding of this highly virulent pathogen is critical, but a large number of knowledge gaps remain. Perhaps first and foremost is a lack of awareness of hvKP and its clinical manifestations, particularly among physicians in Western countries. The epidemiology of hvKP strains has had some recent advances, yet overall it remains poorly understood. An increased understanding of reservoirs, acquisition, and the route(s) of entry may enable prevention of disease. Are all hvKP strains “string-test” positive? The development of a more objective diagnostic test that can be employed by the clinical microbiology laboratory to reliably identify hvKP strains is requisite. This will enhance our ability to perform more comprehensive epidemiologic studies. It will also enable the full spectrum of infectious syndromes and the incidence of infection, especially outside of the Asian Pacific Rim to be defined. It will also assist the clinicians in disease management. The knowledge that an hvKP strain is causing infection should prompt a search for concomitant or subsequent



metastatic sites of infection, which may require drainage or a site-driven modification of the antimicrobial regimen. It is critical to be particularly vigilant for endophthalmitis and CNS infection. Anecdotal data suggests that hvKP reinfection or relapse may develop months to years after treatment has been completed; thereby long-term follow-up will be necessary. Lastly, a more objective diagnostic test will enable studies on whether the nature and duration of therapy for hvKP infection should be different from cKP and other enteric GNB. It will be important to identify traits, other than the ability of hvKP strains to more efficiently acquire iron,<sup>57</sup> that are responsible for their enhanced virulence compared with cKP strains. The hypermucoviscous phenotype may also qualify, but additional studies are needed. A critical and fascinating question is why do hvKP strains have the propensity for metastatic spread. This is a highly unusual trait for enteric GNB and to date we have no insight into the cause for this dangerous clinical manifestation. Potential antimicrobial or vaccine targets must be identified and validated as

well. This information is desperately needed for the development of preventative and novel therapeutic measures. Time is of the essence. The prospect of a hypervirulent pathogen that is capable of causing severe infection in healthy, ambulatory individuals is concerning enough. If one adds the likelihood that hvKP strains will acquire extreme or pan-antimicrobial resistance in the near future, the scenario becomes truly frightening.

#### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

#### Acknowledgments

This work was supported in part by the National Institutes of Health grant 1R21AI088318-01A1 (T.A.R.) and by a VA Merit Review from the Department of Veterans Affairs (T.A.R.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The pictures used in Figures 1 and 2 were kindly provided by Dr. John Crane.

#### References

- Montgomery JZ. Epidemiology of Klebsiella and hospital-associated infections. *Rev Infect Dis* 1979; 1:736-53; PMID:396632; <http://dx.doi.org/10.1093/clindis/1.5.736>.
- Podschnur R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clin Microbiol Rev* 1998; 11:589-603; PMID:9767057.
- Gupta A. Hospital-acquired infections in the neonatal intensive care unit—Klebsiella pneumoniae. *Semin Perinatol* 2002; 26:340-5; PMID:12452506; <http://dx.doi.org/10.1053/sper.2002.36267>.
- Ko WC, Paterson DL, Sagnimeni AJ, Hansen DS, Von Gottberg A, Mohapatra S, et al. Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. *Emerg Infect Dis* 2002; 8:160-6; PMID:11897067; <http://dx.doi.org/10.3201/eid0802.010025>.
- Moellering RC Jr. NDM-1—a cause for worldwide concern. *N Engl J Med* 2010; 363:2377-9; PMID:21158655; <http://dx.doi.org/10.1056/NEJMp1011715>.
- Snitkin ES, Zelazny AM, Thomas PJ, Stock F, Henderson DK, Palmore TN, et al. NISC Comparative Sequencing Program Group. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. *Sci Transl Med* 2012; 4:ra116; PMID:22914622; <http://dx.doi.org/10.1126/scitranslmed.3004129>.
- Cheng DL, Liu YC, Yen MY, Liu CY, Wang RS. Septic metastatic lesions of pyogenic liver abscess. Their association with Klebsiella pneumoniae bacteremia in diabetic patients. *Arch Intern Med* 1991; 151:1557-9; PMID:1872659; <http://dx.doi.org/10.1001/archinte.1991.00400080059010>.
- Liu YC, Cheng DL, Lin CL. Klebsiella pneumoniae liver abscess associated with septic endophthalmitis. *Arch Intern Med* 1986; 146:1913-6; PMID:3532983; <http://dx.doi.org/10.1001/archinte.1986.00360220057011>.
- Wang JH, Liu YC, Lee SS, Yen MY, Chen YS, Wang JH, et al. Primary liver abscess due to Klebsiella pneumoniae in Taiwan. *Clin Infect Dis* 1998; 26:1434-8; PMID:9636876; <http://dx.doi.org/10.1086/516369>.
- Fierer J, Walls L, Chu P. Recurring Klebsiella pneumoniae pyogenic liver abscesses in a resident of San Diego, California, due to a K1 strain carrying the virulence plasmid. *J Clin Microbiol* 2011; 49:4371-3; PMID:21998428; <http://dx.doi.org/10.1128/JCM.05658-11>.
- McCabe R, Lambert L, Frazee B. Invasive Klebsiella pneumoniae infections, California, USA. *Emerg Infect Dis* 2010; 16:1490-1; PMID:20735943; <http://dx.doi.org/10.3201/eid1609.100386>.
- Keynan Y, Karlowsky JA, Walus T, Rubinstein E. Pyogenic liver abscess caused by hypermucoviscous Klebsiella pneumoniae. *Scand J Infect Dis* 2007; 39:828-30; PMID:17701725; <http://dx.doi.org/10.1080/00365540701266763>.
- Lederman ER, Crum NF. Pyogenic liver abscess with a focus on Klebsiella pneumoniae as a primary pathogen: an emerging disease with unique clinical characteristics. *Am J Gastroenterol* 2005; 100:322-31; PMID:15667489; <http://dx.doi.org/10.1111/j.1572-0241.2005.40310.x>.
- Pastagia M, Arumugam V. Klebsiella pneumoniae liver abscesses in a public hospital in Queens, New York. *Travel Med Infect Dis* 2008; 6:228-33; PMID:18571114; <http://dx.doi.org/10.1016/j.tmaid.2008.02.005>.
- Pomakova DK, Hsiao CB, Beanan JM, Olson R, Macdonald U, Keynan Y, et al. Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumoniae: an emerging and under-recognized pathogenic variant. *Eur J Clin Microbiol Infect Dis* 2012; 31:981-9; PMID:21918907; <http://dx.doi.org/10.1007/s10096-011-1396-6>.
- Nadasy KA, Domiati-Saad R, Tribble MA. Invasive Klebsiella pneumoniae syndrome in North America. *Clin Infect Dis* 2007; 45:e25-8; PMID:17599300; <http://dx.doi.org/10.1086/519424>.
- Frazee BW, Hansen S, Lambert L. Invasive infection with hypermucoviscous Klebsiella pneumoniae: multiple cases presenting to a single emergency department in the United States. *Ann Emerg Med* 2009; 53:639-42; PMID:19135282; <http://dx.doi.org/10.1016/j.annemergmed.2008.11.007>.
- Vila A, Cassata A, Pagella H, Amadio C, Yeh KM, Chang FY, et al. Appearance of Klebsiella pneumoniae liver abscess syndrome in Argentina: case report and review of molecular mechanisms of pathogenesis. *Open Microbiol J* 2011; 5:107-13; PMID:22145012; <http://dx.doi.org/10.2174/1874285801105010107>.
- Doud MS, Grimes-Zeppegno R, Molina E, Miller N, Balachandrar D, Schnepel L, et al. A k2A-positive Klebsiella pneumoniae causes liver and brain abscess in a Saint Kitt's man. *Int J Med Sci* 2009; 6:301-4; PMID:19774200; <http://dx.doi.org/10.7150/ijms.6.301>.
- Decré D, Verdét C, Emirian A, Le Gourrierec T, Petit JC, Offenstadt G, et al. Emerging severe and fatal infections due to Klebsiella pneumoniae in two university hospitals in France. *J Clin Microbiol* 2011; 49:3012-4; PMID:21677064; <http://dx.doi.org/10.1128/JCM.00676-11>.
- Gunnarsson GL, Brandt PB, Gad D, Struve C, Justesen US. Monomicrobial necrotizing fasciitis in a white male caused by hypermucoviscous Klebsiella pneumoniae. *J Med Microbiol* 2009; 58:1519-21; PMID:19661201; <http://dx.doi.org/10.1099/jmm.0.011064-0>.
- Sobirsk SK, Struve C, Jacobsson SG. Primary Klebsiella pneumoniae Liver Abscess with Metastatic Spread to Lung and Eye, a North-European Case Report of an Emerging Syndrome. *Open Microbiol J* 2010; 4:5-7; PMID:20448814; <http://dx.doi.org/10.2174/1874285801004010005>.
- Turton JF, Englander H, Gabriel SN, Turton SE, Kaufmann ME, Pitt TL. Genetically similar isolates of Klebsiella pneumoniae serotype K1 causing liver abscesses in three continents. *J Med Microbiol* 2007; 56:593-7; PMID:17446279; <http://dx.doi.org/10.1099/jmm.0.46964-0>.
- Enani MA, El-Khizzi NA. Community acquired Klebsiella pneumoniae, K1 serotype. Invasive liver abscess with bacteremia and endophthalmitis. *Saudi Med J* 2012; 33:782-6; PMID:22821314.
- Yu VL, Hansen DS, Ko WC, Sagnimeni A, Klugman KP, von Gottberg A, et al. International Klebsiella Study Group. Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections. *Emerg Infect Dis* 2007; 13:986-93; PMID:18214169; <http://dx.doi.org/10.3201/eid1307.070187>.
- Fang CT, Lai SY, Yi WC, Hsueh PR, Liu KL, Chang SC. Klebsiella pneumoniae genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. *Clin Infect Dis* 2007; 45:284-93; PMID:17599305; <http://dx.doi.org/10.1086/519262>.
- Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. *J Clin Microbiol* 2005; 43:4178-82; PMID:16081970; <http://dx.doi.org/10.1128/JCM.43.8.4178-4182.2005>.
- Chung DR, Lee HR, Lee SS, Kim SW, Chang HH, Jung SI, et al. Evidence for clonal dissemination of the serotype K1 Klebsiella pneumoniae strain causing invasive liver abscesses in Korea. *J Clin Microbiol* 2008; 46:4061-3; PMID:18971367; <http://dx.doi.org/10.1128/JCM.01577-08>.

29. Brisse S, Fevre C, Passet V, Issenhuth-Jeanjean S, Tournebise R, Diancourt L, et al. Virulent clones of *Klebsiella pneumoniae*: identification and evolutionary scenario based on genomic and phenotypic characterization. *PLoS One* 2009; 4:e4982; PMID:19319196; <http://dx.doi.org/10.1371/journal.pone.0004982>.
30. Merlet A, Cazanave C, Dutronc H, de Barbeyrac B, Brisse S, Dupon M. Primary liver abscess due to CC23-K1 virulent clone of *Klebsiella pneumoniae* in France. *Clin Microbiol Infect* 2012; 18:E338-9; PMID:22757694; <http://dx.doi.org/10.1111/j.1469-0691.2012.03953.x>.
31. Bialek-Davenet S, Nicolas-Chanoine MH, Decré D, Brisse S. Microbiological and clinical characteristics of bacteraemia caused by the hypermucoviscosity phenotype of *Klebsiella pneumoniae* in Korea. *Epidemiol Infect* 2012; In press; PMID:23006593; <http://dx.doi.org/10.1017/S0950268812002051>.
32. Wu KM, Li LH, Yan JJ, Tsao N, Liao TL, Tsai HC, et al. Genome sequencing and comparative analysis of *Klebsiella pneumoniae* NTUH-K2044, a strain causing liver abscess and meningitis. *J Bacteriol* 2009; 191:4492-501; PMID:19447910; <http://dx.doi.org/10.1128/JB.00315-09>.
33. Fung CP, Lin YT, Lin JC, Chen TL, Yeh KM, Chang FY, et al. *Klebsiella pneumoniae* in gastrointestinal tract and pyogenic liver abscess. *Emerg Infect Dis* 2012; 18:1322-5; PMID:22840473; <http://dx.doi.org/10.3201/eid1808.111053>.
34. Chung DR, Lee H, Park MH, Jung SI, Chang HH, Kim YS, et al. Fecal carriage of serotype K1 *Klebsiella pneumoniae* ST23 strains closely related to liver abscess isolates in Koreans living in Korea. *Eur J Clin Microbiol Infect Dis* 2012; 31:481-6; PMID:21739348; <http://dx.doi.org/10.1007/s10096-011-1334-7>.
35. Lin YT, Siu LK, Lin JC, Chen TL, Tseng CP, Yeh KM, et al. Seroepidemiology of *Klebsiella pneumoniae* colonizing the intestinal tract of healthy Chinese and overseas Chinese adults in Asian countries. *BMC Microbiol* 2012; 12:13; PMID:22260182; <http://dx.doi.org/10.1186/1471-2180-12-13>.
36. Hsu CR, Lin TL, Chen YC, Chou HC, Wang JT. The role of *Klebsiella pneumoniae* rmpA in capsular polysaccharide synthesis and virulence revisited. *Microbiology* 2011; 157:3446-57; PMID:21964731; <http://dx.doi.org/10.1099/mic.0.050336-0>.
37. Yeh KM, Kurup A, Siu LK, Koh YL, Fung CP, Lin JC, et al. Capsular serotype K1 or K2, rather than magA and rmpA, is a major virulence determinant for *Klebsiella pneumoniae* liver abscess in Singapore and Taiwan. *J Clin Microbiol* 2007; 45:466-71; PMID:17151209; <http://dx.doi.org/10.1128/JCM.01150-06>.
38. Yu WL, Ko WC, Cheng KC, Lee CC, Lai CC, Chuang YC. Comparison of prevalence of virulence factors for *Klebsiella pneumoniae* liver abscesses between isolates with capsular K1/K2 and non-K1/K2 serotypes. *Diagn Microbiol Infect Dis* 2008; 62:1-6; PMID:18486404; <http://dx.doi.org/10.1016/j.diagmicrobio.2008.04.007>.
39. Harada S, Tateda K, Mitsui H, Hattori Y, Okubo M, Kimura S, et al. Familial spread of a virulent clone of *Klebsiella pneumoniae* causing primary liver abscess. *J Clin Microbiol* 2011; 49:2354-6; PMID:21490191; <http://dx.doi.org/10.1128/JCM.00034-11>.
40. Johnson JR, Russo TA. Molecular epidemiology of extraintestinal pathogenic (uropathogenic) *Escherichia coli*. *Int J Med Microbiol* 2005; 295:383-404; PMID:16238015; <http://dx.doi.org/10.1016/j.ijmm.2005.07.005>.
41. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis* 2010; 10:597-602; PMID:20705517; [http://dx.doi.org/10.1016/S1473-3099\(10\)70143-2](http://dx.doi.org/10.1016/S1473-3099(10)70143-2).
42. Lee HC, Chuang YC, Yu WL, Lee NY, Chang CM, Ko NY, et al. Clinical implications of hypermucoviscosity phenotype in *Klebsiella pneumoniae* isolates: association with invasive syndrome in patients with community-acquired bacteraemia. *J Intern Med* 2006; 259:606-14; PMID:16704562; <http://dx.doi.org/10.1111/j.1365-2796.2006.01641.x>.
43. Lin YT, Jeng YY, Chen TL, Fung CP. Bacteremic community-acquired pneumonia due to *Klebsiella pneumoniae*: clinical and microbiological characteristics in Taiwan, 2001-2008. *BMC Infect Dis* 2010; 10:307; PMID:20973971; <http://dx.doi.org/10.1186/1471-2334-10-307>.
44. Tu YC, Lu MC, Chiang MK, Huang SP, Peng HL, Chang HY, et al. Genetic requirements for *Klebsiella pneumoniae*-induced liver abscess in an oral infection model. *Infect Immun* 2009; 77:2657-71; PMID:19433545; <http://dx.doi.org/10.1128/IAI.01523-08>.
45. Lowy FD. *Staphylococcus aureus* infections. *N Engl J Med* 1998; 339:520-32; PMID:9709046; <http://dx.doi.org/10.1056/NEJM199808203390806>.
46. Favre-Bonté S, Licht TR, Forestier C, Krogfelt KA. *Klebsiella pneumoniae* capsule expression is necessary for colonization of large intestines of streptomycin-treated mice. *Infect Immun* 1999; 67:6152-6; PMID:10531279.
47. Struve C, Forestier C, Krogfelt KA. Application of a novel multi-screening signature-tagged mutagenesis assay for identification of *Klebsiella pneumoniae* genes essential in colonization and infection. *Microbiology* 2003; 149:167-76; PMID:12576590; <http://dx.doi.org/10.1099/mic.0.25833-0>.
48. Maroncle N, Balestrino D, Rich C, Forestier C. Identification of *Klebsiella pneumoniae* genes involved in intestinal colonization and adhesion using signature-tagged mutagenesis. *Infect Immun* 2002; 70:4729-34; PMID:12117993; <http://dx.doi.org/10.1128/IAI.70.8.4729-4734.2002>.
49. Lin CT, Huang TY, Liang WC, Peng HL. Homologous response regulators KvgA, KvhA and KvhR regulate the synthesis of capsular polysaccharide in *Klebsiella pneumoniae* CG43 in a coordinated manner. *J Biochem* 2006; 140:429-38; PMID:16877448; <http://dx.doi.org/10.1093/jb/mvj168>.
50. Hsieh PF, Lin TL, Lee CZ, Tsai SF, Wang JT. Serum-induced iron-acquisition systems and TonB contribute to virulence in *Klebsiella pneumoniae* causing primary pyogenic liver abscess. *J Infect Dis* 2008; 197:1717-27; PMID:18433330; <http://dx.doi.org/10.1086/588383>.
51. Ma LC, Fang CT, Lee CZ, Shun CT, Wang JT. Genomic heterogeneity in *Klebsiella pneumoniae* strains is associated with primary pyogenic liver abscess and metastatic infection. *J Infect Dis* 2005; 192:117-28; PMID:15942901; <http://dx.doi.org/10.1086/430619>.
52. Chou HC, Lee CZ, Ma LC, Fang CT, Chang SC, Wang JT. Isolation of a chromosomal region of *Klebsiella pneumoniae* associated with allantoin metabolism and liver infection. *Infect Immun* 2004; 72:3783-92; PMID:15213119; <http://dx.doi.org/10.1128/IAI.72.7.3783-3792.2004>.
53. Wu MC, Lin TL, Hsieh PF, Yang HC, Wang JT. Isolation of genes involved in biofilm formation of a *Klebsiella pneumoniae* strain causing pyogenic liver abscess. *PLoS One* 2011; 6:e23500; PMID:21858144; <http://dx.doi.org/10.1371/journal.pone.0023500>.
54. Wu MC, Chen YC, Lin TH, Hsieh PF, Wang JT. Cellobiose-specific phosphotransferase system of *Klebsiella pneumoniae* and its importance in biofilm formation and virulence. *Infect Immun* 2012; 80:2464-72; PMID:22566508; <http://dx.doi.org/10.1128/IAI.06247-11>.
55. Chen YT, Chang HY, Lai YC, Pan CC, Tsai SF, Peng HL. Sequencing and analysis of the large virulence plasmid pLVPK of *Klebsiella pneumoniae* CG43. *Gene* 2004; 337:189-98; PMID:15276215; <http://dx.doi.org/10.1016/j.gene.2004.05.008>.
56. Nassif X, Sansonetti PJ. Correlation of the virulence of *Klebsiella pneumoniae* K1 and K2 with the presence of a plasmid encoding aerobactin. *Infect Immun* 1986; 54:603-8; PMID:2946641.
57. Russo TA, Shon AS, Beanan JM, Olson R, MacDonald U, Pomakov AO, et al. Hypervirulent *K. pneumoniae* secretes more and more active iron-acquisition molecules than "classical" *K. pneumoniae* thereby enhancing its virulence. *PLoS One* 2011; 6:e26734; PMID:22039542; <http://dx.doi.org/10.1371/journal.pone.0026734>.
58. Ward CG, Hammond JS, Bullen JJ. Effect of iron compounds on antibacterial function of human polymorphs and plasma. *Infect Immun* 1986; 51:723-30; PMID:3512430.
59. Garénaux A, Caza M, Dozois CM. The Ins and Outs of siderophore mediated iron uptake by extraintestinal pathogenic *Escherichia coli*. *Vet Microbiol* 2011; 153:89-98; PMID:21680117; <http://dx.doi.org/10.1016/j.vetmic.2011.05.023>.
60. Nassif X, Fournier JM, Arondel J, Sansonetti PJ. Mucoid phenotype of *Klebsiella pneumoniae* is a plasmid-encoded virulence factor. *Infect Immun* 1989; 57:546-52; PMID:2643575.
61. Cheng HY, Chen YS, Wu CY, Chang HY, Lai YC, Peng HL. RmpA regulation of capsular polysaccharide biosynthesis in *Klebsiella pneumoniae* CG43. *J Bacteriol* 2010; 192:3144-58; PMID:20382770; <http://dx.doi.org/10.1128/JB.00031-10>.
62. Wacharatayankun R, Arakawa Y, Ohta M, Tanaka K, Akashi T, Mori M, et al. Enhancement of extracellular polysaccharide synthesis in *Klebsiella pneumoniae* by RmpA2, which shows homology to NtrC and FixJ. *Infect Immun* 1993; 61:3164-74; PMID:8335346.
63. Yeh KM, Lin JC, Yin FY, Fung CP, Hung HC, Siu LK, et al. Revisiting the importance of virulence determinant magA and its surrounding genes in *Klebsiella pneumoniae* causing pyogenic liver abscesses: exact role in serotype K1 capsule formation. *J Infect Dis* 2010; 201:1259-67; PMID:19785524; <http://dx.doi.org/10.1086/606010>.
64. Lai YC, Peng HL, Chang HY. RmpA2, an activator of capsule biosynthesis in *Klebsiella pneumoniae* CG43, regulates K2 cps gene expression at the transcriptional level. *J Bacteriol* 2003; 185:788-800; PMID:12533454; <http://dx.doi.org/10.1128/JB.185.3.788-800.2003>.
65. Majdalani N, Gottesman S. The Rcs phosphorelay: a complex signal transduction system. *Annu Rev Microbiol* 2005; 59:379-405; PMID:16153174; <http://dx.doi.org/10.1146/annurev.micro.59.050405.101230>.
66. Lin CT, Wu CC, Chen YS, Lai YC, Chi C, Lin JC, et al. Fur regulation of the capsular polysaccharide biosynthesis and iron-acquisition systems in *Klebsiella pneumoniae* CG43. *Microbiology* 2011; 157:419-29; PMID:21071493; <http://dx.doi.org/10.1099/mic.0.044065-0>.
67. Lin YC, Lu MC, Tang HL, Liu HC, Chen CH, Liu KS, et al. Assessment of hypermucoviscosity as a virulence factor for experimental *Klebsiella pneumoniae* infections: comparative virulence analysis with hypermucoviscosity-negative strain. *BMC Microbiol* 2011; 11:50; PMID:21385400; <http://dx.doi.org/10.1186/1471-2180-11-50>.
68. Pan YJ, Fang HC, Yang HC, Lin TL, Hsieh PF, Tsai FC, et al. Capsular polysaccharide synthesis regions in *Klebsiella pneumoniae* serotype K57 and a new capsular serotype. *J Clin Microbiol* 2008; 46:2231-40; PMID:18508935; <http://dx.doi.org/10.1128/JCM.01716-07>.
69. Simoons-Smit AM, Verweij-van Vught AM, MacLaren DM. The role of K antigens as virulence factors in *Klebsiella*. *J Med Microbiol* 1986; 21:133-7; PMID:3512838; <http://dx.doi.org/10.1099/00222615-21-2-133>.

70. Clements A, Gaboriaud F, Duval JF, Farn JL, Jenney AW, Lithgow T, et al. The major surface-associated saccharides of *Klebsiella pneumoniae* contribute to host cell association. *PLoS One* 2008; 3:e3817; PMID:19043570; <http://dx.doi.org/10.1371/journal.pone.0003817>.
71. Merino S, Camprubí S, Albertí S, Benedí VJ, Tomás JM. Mechanisms of *Klebsiella pneumoniae* resistance to complement-mediated killing. *Infect Immun* 1992; 60:2529-35; PMID:1587619.
72. Cortés G, Borrell N, de Astorza B, Gómez C, Sauleda J, Albertí S. Molecular analysis of the contribution of the capsular polysaccharide and the lipopolysaccharide O side chain to the virulence of *Klebsiella pneumoniae* in a murine model of pneumonia. *Infect Immun* 2002; 70:2583-90; PMID:11953399; <http://dx.doi.org/10.1128/IAI.70.5.2583-2590.2002>.
73. Lawlor MS, Hsu J, Rick PD, Miller VL. Identification of *Klebsiella pneumoniae* virulence determinants using an intranasal infection model. *Mol Microbiol* 2005; 58:1054-73; PMID:16262790; <http://dx.doi.org/10.1111/j.1365-2958.2005.04918.x>.
74. Chuang YP, Fang CT, Lai SY, Chang SC, Wang JT. Genetic determinants of capsular serotype K1 of *Klebsiella pneumoniae* causing primary pyogenic liver abscess. *J Infect Dis* 2006; 193:645-54; PMID:16453259; <http://dx.doi.org/10.1086/499968>.
75. Cheng NC, Yu YC, Tai HC, Hsueh PR, Chang SC, Lai SY, et al. Recent Trend of Necrotizing Fasciitis in Taiwan: Focus on Monomicrobial *Klebsiella pneumoniae* Necrotizing Fasciitis. *Clin Infect Dis* 2012; 55:930-9; PMID:22715175; <http://dx.doi.org/10.1093/cid/cis565>.
76. Chung DR, Lee SS, Lee HR, Kim HB, Choi HJ, Eom JS, et al.; Korean Study Group for Liver Abscess. Emerging invasive liver abscess caused by K1 serotype *Klebsiella pneumoniae* in Korea. *J Infect* 2007; 54:578-83; PMID:17175028; <http://dx.doi.org/10.1016/j.jinf.2006.11.008>.
77. Whitfield C, Perry MB, MacLean LL, Yu SH. Structural analysis of the O-antigen side chain polysaccharides in the lipopolysaccharides of *Klebsiella* serotypes O2(2a), O2(2a,2b), and O2(2a,2c). *J Bacteriol* 1992; 174:4913-9; PMID:1378428.
78. Camprubí S, Merino S, Benedí VJ, Tomás JM. The role of the O-antigen lipopolysaccharide and capsule on an experimental *Klebsiella pneumoniae* infection of the rat urinary tract. *FEMS Microbiol Lett* 1993; 111:9-13; PMID:7689524; [http://dx.doi.org/10.1016/0378-1097\(93\)90175-2](http://dx.doi.org/10.1016/0378-1097(93)90175-2).
79. Lugo JZ, Price S, Miller JE, Ben-David I, Merrill VA, Mancuso P, et al. Lipopolysaccharide O-antigen promotes persistent murine bacteremia. *Shock* 2007; 27:186-91; PMID:17224794; <http://dx.doi.org/10.1097/01.shk.0000238058.23837.21>.
80. Clements A, Tull D, Jenney AW, Farn JL, Kim SH, Bishop RE, et al. Secondary acylation of *Klebsiella pneumoniae* lipopolysaccharide contributes to sensitivity to antibacterial peptides. *J Biol Chem* 2007; 282:15569-77; PMID:17371870; <http://dx.doi.org/10.1074/jbc.M701454200>.
81. Hsieh PF, Lin TL, Yang FL, Wu MC, Pan YJ, Wu SH, et al. Lipopolysaccharide O1 antigen contributes to the virulence in *Klebsiella pneumoniae* causing pyogenic liver abscess. *PLoS One* 2012; 7:e33155; PMID:22427976; <http://dx.doi.org/10.1371/journal.pone.0033155>.
82. Rosen DA, Pinkner JS, Jones JM, Walker JN, Clegg S, Hultgren SJ. Utilization of an intracellular bacterial community pathway in *Klebsiella pneumoniae* urinary tract infection and the effects of FimK on type 1 pilus expression. *Infect Immun* 2008; 76:3337-45; PMID:18411285; <http://dx.doi.org/10.1128/IAI.00090-08>.
83. Hornick DB, Allen BL, Horn MA, Clegg S. Adherence to respiratory epithelia by recombinant *Escherichia coli* expressing *Klebsiella pneumoniae* type 3 fimbrial gene products. *Infect Immun* 1992; 60:1577-88; PMID:1312518.
84. Wu CC, Lin CT, Cheng WY, Huang CJ, Wang ZC, Peng HL. Fur-dependent MrkHI regulation of type 3 fimbriae in *Klebsiella pneumoniae* CG43. *Microbiology* 2012; 158:1045-56; PMID:22262101; <http://dx.doi.org/10.1099/mic.0.053801-0>.
85. Di Martino P, Bertin Y, Girardeau JP, Livrelli V, Joly B, Darfeuille-Michaud A. Molecular characterization and adhesive properties of CF29K, an adhesin of *Klebsiella pneumoniae* strains involved in nosocomial infections. *Infect Immun* 1995; 63:4336-44; PMID:7591068.
86. Thornton MM, Chung-Esaki HM, Irvin CB, Bortz DM, Solomon MJ, Younger JG. Multicellularity and antibiotic resistance in *Klebsiella pneumoniae* grown under bloodstream-mimicking fluid dynamic conditions. *J Infect Dis* 2012; 206:588-95; PMID:22711903; <http://dx.doi.org/10.1093/infdis/jis397>.
87. Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. *Trends Microbiol* 2005; 13:34-40; PMID:15639630; <http://dx.doi.org/10.1016/j.tim.2004.11.010>.
88. Bakaletz LO. Bacterial biofilms in otitis media: evidence and relevance. *Pediatr Infect Dis J* 2007; 26(Suppl):S17-9; PMID:18049376; <http://dx.doi.org/10.1097/INF.0b013e318154b273>.
89. Ricucci D, Siqueira JF Jr. Biofilms and apical periodontitis: study of prevalence and association with clinical and histopathologic findings. *J Endod* 2010; 36:1277-88; PMID:20647081; <http://dx.doi.org/10.1016/j.joen.2010.04.007>.
90. Yamanaka T, Yamane K, Furukawa T, Matsumoto-Mashimo C, Sugimori C, Nambu T, et al. Comparison of the virulence of exopolysaccharide-producing *Prevotella intermedia* to exopolysaccharide non-producing periodontopathic organisms. *BMC Infect Dis* 2011; 11:228; PMID:21864411; <http://dx.doi.org/10.1186/1471-2334-11-228>.
91. Langstraat J, Bohse M, Clegg S. Type 3 fimbrial shaft (MrkA) of *Klebsiella pneumoniae*, but not the fimbrial adhesin (MrkD), facilitates biofilm formation. *Infect Immun* 2001; 69:5805-12; PMID:11500458; <http://dx.doi.org/10.1128/IAI.69.9.5805-5812.2001>.
92. Wilksch JJ, Yang J, Clements A, Gabbe JL, Short KR, Cao H, et al. MrkH, a novel c-di-GMP-dependent transcriptional activator, controls *Klebsiella pneumoniae* biofilm formation by regulating type 3 fimbriae expression. *PLoS Pathog* 2011; 7:e1002204; PMID:21901098; <http://dx.doi.org/10.1371/journal.ppat.1002204>.
93. Balestrino D, Ghigo JM, Charbonnel N, Haagensen JA, Forestier C. The characterization of functions involved in the establishment and maturation of *Klebsiella pneumoniae* in vitro biofilm reveals dual roles for surface exopolysaccharides. *Environ Microbiol* 2008; 10:685-701; PMID:18237304; <http://dx.doi.org/10.1111/j.1462-2920.2007.01491.x>.
94. Boddicker JD, Anderson RA, Jagnow J, Clegg S. Signature-tagged mutagenesis of *Klebsiella pneumoniae* to identify genes that influence biofilm formation on extracellular matrix material. *Infect Immun* 2006; 74:4590-7; PMID:16861646; <http://dx.doi.org/10.1128/IAI.00129-06>.
95. Stahlhut SG, Schroll C, Harmsen M, Struve C, Krogfelt KA. Screening for genes involved in *Klebsiella pneumoniae* biofilm formation using a fosmid library. *FEMS Immunol Med Microbiol* 2010; 59:521-4; PMID:20482632.
96. Hennequin C, Forestier C. *oxyR*, a LysR-type regulator involved in *Klebsiella pneumoniae* mucosal and abiotic colonization. *Infect Immun* 2009; 77:5449-57; PMID:19786563; <http://dx.doi.org/10.1128/IAI.00837-09>.
97. Pan PC, Chen HW, Wu PK, Wu YY, Lin CH, Wu JH. Mutation in fucose synthesis gene of *Klebsiella pneumoniae* affects capsule composition and virulence in mice. *Exp Biol Med* (Maywood) 2011; 236:219-26; PMID:21321319; <http://dx.doi.org/10.1258/ebm.2010.010193>.
98. Kong Q, Beanan JM, Olson R, Macdonald U, Shon AS, Metzger DJ, et al. Biofilm formed by a hyper-virulent (hypermucoviscous) variant of *Klebsiella pneumoniae* does not enhance serum resistance or survival in an in vivo abscess model. *Virulence* 2012; 3:309-18; PMID:22546898; <http://dx.doi.org/10.4161/viru.20383>.
99. Han SH. Review of hepatic abscess from *Klebsiella pneumoniae*. An association with diabetes mellitus and septic endophthalmitis. *West J Med* 1995; 162:220-4; PMID:7725704.
100. Tsay RW, Siu LK, Fung CP, Chang FY. Characteristics of bacteremia between community-acquired and nosocomial *Klebsiella pneumoniae* infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. *Arch Intern Med* 2002; 162:1021-7; PMID:11996612; <http://dx.doi.org/10.1001/archinte.162.9.1021>.
101. Huang CR, Lu CH, Chang HW, Lee PY, Lin MW, Chang WN. Community-acquired spontaneous bacterial meningitis in adult diabetic patients: an analysis of clinical characteristics and prognostic factors. *Infection* 2002; 30:346-50; PMID:12478323; <http://dx.doi.org/10.1007/s15010-002-3010-4>.
102. Chen SC, Yen CH, Tsao SM, Huang CC, Chen CC, Lee MC, et al. Comparison of pyogenic liver abscesses of biliary and cryptogenic origin. An eight-year analysis in a University Hospital. *Swiss Med Wkly* 2005; 135:344-51; PMID:16059789.
103. Kim JK, Chung DR, Wie SH, Yoo JH, Park SW; Korean Study Group for Liver Abscess. Risk factor analysis of invasive liver abscess caused by the K1 serotype *Klebsiella pneumoniae*. *Eur J Clin Microbiol Infect Dis* 2009; 28:109-11; PMID:18663497; <http://dx.doi.org/10.1007/s10096-008-0595-2>.
104. Fang CT, Chen YC, Chang SC, Sau WY, Luh KT. *Klebsiella pneumoniae* meningitis: timing of antimicrobial therapy and prognosis. *QJM* 2000; 93:45-53; PMID:10623782; <http://dx.doi.org/10.1093/qjmed/93.1.45>.
105. Ku YH, Chuang YC, Yu WL. Clinical spectrum and molecular characteristics of *Klebsiella pneumoniae* causing community-acquired extrahepatic abscess. *J Microbiol Immunol Infect* 2008; 41:311-7; PMID:18787738.
106. Tsai FC, Huang YT, Chang LY, Wang JT. Pyogenic liver abscess as endemic disease, Taiwan. *Emerg Infect Dis* 2008; 14:1592-600; PMID:18826824; <http://dx.doi.org/10.3201/eid1410.071254>.
107. Rahimian J, Wilson T, Oram V, Holzman RS. Pyogenic liver abscess: recent trends in etiology and mortality. *Clin Infect Dis* 2004; 39:1654-9; PMID:15578367; <http://dx.doi.org/10.1086/425616>.
108. Pope JV, Teich DL, Clardy P, McGillicuddy DC. *Klebsiella pneumoniae* liver abscess: an emerging problem in North America. *J Emerg Med* 2011; 41:e103-5; PMID:18993020; <http://dx.doi.org/10.1016/j.jemermed.2008.04.041>.
109. Chang CM, Ko WC, Lee HC, Chen YM, Chuang YC. *Klebsiella pneumoniae* psoas abscess: predominance in diabetic patients and grave prognosis in gas-forming cases. *J Microbiol Immunol Infect* 2001; 34:201-6; PMID:11605812.
110. Lee WS, Choi ST, Kim KK. Splenic abscess: a single institution study and review of the literature. *Yonsei Med J* 2011; 52:288-92; PMID:21319348; <http://dx.doi.org/10.3349/ymj.2011.52.2.288>.
111. Chang KC, Chuah SK, Changchien CS, Tsai TL, Lu SN, Chiu YC, et al. Clinical characteristics and prognostic factors of splenic abscess: a review of 67 cases in a single medical center of Taiwan. *World J Gastroenterol* 2006; 12:460-4; PMID:16489650.
112. Tung CC, Chen FC, Lo CJ. Splenic abscess: an easily overlooked disease? *Am Surg* 2006; 72:322-5; PMID:16676856.

113. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. *Rev Infect Dis* 1989; 11:586-99; PMID:2772465; <http://dx.doi.org/10.1093/clinids/11.4.586>.
114. Lin YT, Chen TL, Siu LK, Hsu SF, Fung CP. Clinical and microbiological characteristics of community-acquired thoracic empyema or complicated parapneumonic effusion caused by *Klebsiella pneumoniae* in Taiwan. *Eur J Clin Microbiol Infect Dis* 2010; 29:1003-10; PMID:20505967; <http://dx.doi.org/10.1007/s10096-010-0961-8>.
115. Tsang KY, Leung WS, Chan VL, Lin AW, Chu CM. Complicated parapneumonic effusion and empyema thoracis: microbiology and predictors of adverse outcomes. *Hong Kong Med J* 2007; 13:178-86; PMID:17548905.
116. Tu CY, Hsu WH, Hsia TC, Chen HJ, Chiu KL, Hang LW, et al. The changing pathogens of complicated parapneumonic effusions or empyemas in a medical intensive care unit. *Intensive Care Med* 2006; 32:570-6; PMID:16479377; <http://dx.doi.org/10.1007/s00134-005-0064-7>.
117. Chou FF, Kou HK. Endogenous endophthalmitis associated with pyogenic hepatic abscess. *J Am Coll Surg* 1996; 182:33-6; PMID:8542086.
118. Chang FY, Chou MY. Comparison of pyogenic liver abscesses caused by *Klebsiella pneumoniae* and non-*K. pneumoniae* pathogens. *J Formos Med Assoc* 1995; 94:232-7; PMID:7613255.
119. Yang CS, Tsai HY, Sung CS, Lin KH, Lee FL, Hsu WM. Endogenous *Klebsiella* endophthalmitis associated with pyogenic liver abscess. *Ophthalmology* 2007; 114:876-80; PMID:17467526; <http://dx.doi.org/10.1016/j.ophtha.2006.12.035>.
120. Sng CC, Jap A, Chan YH, Chee SP. Risk factors for endogenous *Klebsiella* endophthalmitis in patients with *Klebsiella* bacteraemia: a case-control study. *Br J Ophthalmol* 2008; 92:673-7; PMID:18245273; <http://dx.doi.org/10.1136/bjo.2007.132522>.
121. Ang M, Jap A, Chee SP. Prognostic factors and outcomes in endogenous *Klebsiella pneumoniae* endophthalmitis. *Am J Ophthalmol* 2011; 151:338-44, e2; PMID:21168820; <http://dx.doi.org/10.1016/j.ajo.2010.08.036>.
122. Margo CE, Mames RN, Guy JR. Endogenous *Klebsiella* endophthalmitis. Report of two cases and review of the literature. *Ophthalmology* 1994; 101:1298-301; PMID:8035994.
123. Wong JS, Chan TK, Lee HM, Chee SP. Endogenous bacterial endophthalmitis: an east Asian experience and a reappraisal of a severe ocular affliction. *Ophthalmology* 2000; 107:1483-91; PMID:10919895; [http://dx.doi.org/10.1016/S0161-6420\(00\)00216-5](http://dx.doi.org/10.1016/S0161-6420(00)00216-5).
124. Liao HR, Lee HW, Leu HS, Lin BJ, Juang CJ. Endogenous *Klebsiella pneumoniae* endophthalmitis in diabetic patients. *Can J Ophthalmol* 1992; 27:143-7; PMID:1586886.
125. Tang LM, Chen ST, Hsu WC, Chen CM. *Klebsiella* meningitis in Taiwan: an overview. *Epidemiol Infect* 1997; 119:135-42; PMID:9363011; <http://dx.doi.org/10.1017/S0950268897007930>.
126. Jang TN, Wang FD, Wang LS, Yu KW, Liu CY. Gram-negative bacillary meningitis in adults: a recent six-year experience. *J Formos Med Assoc* 1993; 92:540-6; PMID:8106042.
127. Fang CT, Chang SC, Hsueh PR, Chen YC, Sau WY, Luh KT. Microbiologic features of adult community-acquired bacterial meningitis in Taiwan. *J Formos Med Assoc* 2000; 99:300-4; PMID:10870313.
128. Chang WN, Huang CR, Lu CH, Chien CC. Adult *Klebsiella pneumoniae* Meningitis in Taiwan: An Overview. *Acta Neurol Taiwan* 2012; 21:87-96; PMID:22879119.
129. Durand ML, Calderwood SB, Weber DJ, Miller SI, Southwick FS, Caviness VS Jr, et al. Acute bacterial meningitis in adults. A review of 493 episodes. *N Engl J Med* 1993; 328:21-8; PMID:8416268; <http://dx.doi.org/10.1056/NEJM199301073280104>.
130. Lin YT, Liu CJ, Chen TJ, Fung CP. Long-term mortality of patients with septic ocular or central nervous system complications from pyogenic liver abscess: a population-based study. *PLoS One* 2012; 7:e33978; PMID:22479491; <http://dx.doi.org/10.1371/journal.pone.0033978>.
131. Tsou TP, Lee PI, Lu CY, Chang LY, Huang LM, Chen JM, et al. Microbiology and epidemiology of brain abscess and subdural empyema in a medical center: a 10-year experience. *J Microbiol Immunol Infect* 2009; 42:405-12; PMID:20182670.
132. Hsieh MJ, Lu TC, Ma MH, Wang HP, Chen SC. Unrecognized cervical spinal epidural abscess associated with metastatic *Klebsiella pneumoniae* bacteremia and liver abscess in nondiabetic patients. *Diagn Microbiol Infect Dis* 2009; 65:65-8; PMID:19679238; <http://dx.doi.org/10.1016/j.diagmicrobio.2009.05.013>.
133. Kuramochi G, Takei SI, Sato M, Isokawa O, Takemae T, Takahashi A. *Klebsiella pneumoniae* liver abscess associated with septic spinal epidural abscess. *Hepatol Res* 2005; 31:48-52; PMID:15652471; <http://dx.doi.org/10.1016/j.hepres.2004.09.006>.
134. Mita N, Narahara H, Okawa M, Hinohara H, Kunitomo F, Haque A, et al. Necrotizing fasciitis following psoas muscle abscess caused by hypermucoviscous *Klebsiella pneumoniae*. *J Infect Chemother* 2012; 18:565-8; PMID:22065090; <http://dx.doi.org/10.1007/s10156-011-0338-7>.
135. Asgeirsson H, Kristjansson M, Kristinsson KG, Gudlaugsson O. Clinical significance of *Staphylococcus aureus* bacteriuria in a nationwide study of adults with *S. aureus* bacteraemia. *J Infect* 2012; 64:41-6; PMID:22051916; <http://dx.doi.org/10.1016/j.jinf.2011.10.009>.
136. Yang SJ, Park SY, Lee YJ, Kim HY, Seo JA, Kim SG, et al. *Klebsiella pneumoniae* orbital cellulitis with extensive vascular occlusions in a patient with type 2 diabetes. *Korean J Intern Med* 2010; 25:114-7; PMID:20195414; <http://dx.doi.org/10.3904/kjim.2010.25.1.114>.
137. Pinsky BA, Baron EJ, Janda JM, Banaei N. Bartholin's abscess caused by hypermucoviscous *Klebsiella pneumoniae*. *J Med Microbiol* 2009; 58:671-3; PMID:19369531; <http://dx.doi.org/10.1099/jmm.0.006734-0>.
138. Rivero A, Gomez E, Alland D, Huang DB, Chiang T. K2 serotype *Klebsiella pneumoniae* causing a liver abscess associated with infective endocarditis. *J Clin Microbiol* 2010; 48:639-41; PMID:20007381; <http://dx.doi.org/10.1128/JCM.01779-09>.
139. Tsai YJ, Lin YC, Harnnd DJ, Chiang RP, Wu HM. A Lemierre syndrome variant caused by *Klebsiella pneumoniae*. *J Formos Med Assoc* 2012; 111:403-5; PMID:22817819; <http://dx.doi.org/10.1016/j.jfma.2012.03.012>.
140. Elemam A, Rahimian J, Mandell W. Infection with panresistant *Klebsiella pneumoniae*: a report of 2 cases and a brief review of the literature. *Clin Infect Dis* 2009; 49:271-4; PMID:19527172; <http://dx.doi.org/10.1086/600042>.
141. Su SC, Siu LK, Ma L, Yeh KM, Fung CP, Lin JC, et al. Community-acquired liver abscess caused by serotype K1 *Klebsiella pneumoniae* with CTX-M-15-type extended-spectrum beta-lactamase. *Antimicrob Agents Chemother* 2008; 52:804-5; PMID:18056273; <http://dx.doi.org/10.1128/AAC.01269-07>.